Recce Pharmaceuticals Share Price and Company Fundamentals
Last traded: Today at 5:10 AM
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic antiinfectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is Phase II clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as is in Phase I/II clinical trials for topical wound infections and diabetic foot infections. The company has strategic partnership with Murdoch Children's Research Institute for development of the Acinetobacter baumannii and Mycobacterium abscessus; and cooperative research and development agreement with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to be tested against highly hazardous pathogens. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
Key Metrics
PE ratio
-
PB ratio
-
Dividend yield
-
Beta
0.21
Market cap
$166.28M
Enterprise value
$173.11M
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Website | https://www.recce.com.au |
| Mailing address | Governor Macquarie Tower Level 15 1 Farrer Place Sydney NSW 2000 Australia |
| Phone / Fax | 61 2 9000 1907 / |
Dividends
More: Recce Pharmaceuticals Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Recce Pharmaceuticals paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.RCE dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Recce Pharmaceuticals.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. John K. A. Prendergast Ph.D. | Executive Chairman of the Board | 71 | |
| Mr. James Hamilton-Bray Graham GAICD | CEO, MD & Executive Director | ||
| Ms. Michele Keryn Dilizia BA (Journ), BSc (Med Sci) | Chief Scientific Director & Executive Director | ||
| Dr. Justin Ward | Principal Quality Chemist & Executive Director | ||
| Mr. Arthur Kollaras | Principal Engineer & Head of Manufacturing | ||
| Dr. Alan W. Dunton B.Sc., M.D. | Chief Medical Advisor & Independent Non Executive Director | 71 | |
| Mr. Justin Reynolds | Chief Financial Officer | ||
| Mr. Daniel Astudillo B.A., B.Com., M.B.A. | Head of Marketing | ||
| Ms. Maggie Niewidok | Company Secretary |
Profitability and management effectiveness
Profit margin
-285.37%
Operating margin
-2370.00%
Return on assets
-135.80%
Return on equity
-
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Recce Pharmaceuticals is 166.28M and its enterprise value is 173.11M. The enterprise value to revenue ratio of RCE is 23.05. The enterprise value to EBITDA ratio of RCE is -8.51.
The RCE's stocks Beta value is 0.21 making it 79% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Recce Pharmaceuticals (RCE)
Recce Pharmaceuticals (ASX:RCE) Frequently Asked Questions
1. What is Recce Pharmaceuticals's Stock Symbol?
Recce Pharmaceuticals trades on ASX under the ticker symbol "RCE".
2. What is Recce Pharmaceuticals's stock price today?
One share of RCE stock can currently be purchased for approximately $0.575.
3. How can I contact Recce Pharmaceuticals?
Recce Pharmaceuticals's mailing address is Governor Macquarie Tower Level 15 1 Farrer Place Sydney NSW 2000 Australia. The company can be reached via phone at 61 2 9000 1907.
4. What is Recce Pharmaceuticals's official website?
The official website of Recce Pharmaceuticals is https://www.recce.com.au.